Inhibitors of phosphatidylinositol 3-kinase (PI3K) and Bruton tyrosine kinase (BTK) represent a recognized option for the treatment of patients affected by indolent B cell lymphomas. This evidence concerns the gene BTK and indolent B-cell non-Hodgkin lymphoma.